Symbicort 160/4.5 mcg/inhalación
5000456021067- Registrado en
- United Kingdom
- Código del fabricante
- 456
- Código del producto
- 2106
Fotos
Todavía no hay fotos de este producto.
¿Lo tienes a mano? Envía una foto desde la app y consigue 3 créditos de IA cuando se apruebe. Descargar la app
Sobre este producto
Escrito automáticamente a partir de información pública, por lo que puede contener errores. Aún no está disponible en español, así que se muestra en inglés.
Barcode: 5000456021067 – Symbicort 160/4.5 mcg (Inhalation Powder)
This barcode corresponds to Symbicort Turbuhaler 160/4.5 mcg, a combination inhaler used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and children (depending on the formulation). Below are key details:
Product Overview
- Active Ingredients:
- Formoterol fumarate (long-acting β₂-agonist, LABA) – 4.5 mcg per inhalation.
- Budesonide (inhaled corticosteroid, ICS) – 160 mcg per inhalation.
- Formulation: Dry powder for inhalation (Turbuhaler device).
- Manufacturer: Typically AstraZeneca (or a licensed generic manufacturer, as Symbicort is a patented product).
- Prescription Status: Prescription-only medication (not available over-the-counter).
Mechanism of Action
Symbicort combines:
- Budesonide: Reduces airway inflammation (glucocorticoid effect).
- Formoterol: Provides rapid bronchodilation (sympathomimetic effect), with a long duration of action (up to 12 hours).
This dual-action approach is standard for maintenance therapy in persistent asthma/COPD, not for acute relief (e.g., rescue inhalers like albuterol are used separately for symptoms).
Warnings & Concerns
-
Not for Acute Symptoms:
- Formoterol provides rapid bronchodilation, but Symbicort is not a rescue inhaler. Patients should carry a short-acting β₂-agonist (SABA) (e.g., albuterol) for breakthrough symptoms.
- Risk of paradoxical bronchospasm: If used incorrectly (e.g., during acute exacerbations), it may worsen breathing.
-
Increased Asthma-Related Death Risk:
- LABA monotherapy (without ICS) has been linked to higher asthma mortality (per FDA/EMA warnings). Symbicort includes an ICS, mitigating this risk when used as directed.
- Do not use Symbicort alone for asthma control without an ICS component (e.g., if misused as a standalone LABA).
Lee la descripción completa
Ya has leído tus 3 descripciones completas gratuitas de hoy. Crea una cuenta gratuita o inicia sesión para leer todas las descripciones completas, sin límite diario.
Con qué frecuencia se consulta
- Hoy
- 1
- Últimos 7 días
- 10
- Últimos 30 días
- 32
- Desde siempre
- 32